146 related articles for article (PubMed ID: 7636626)
1. Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung.
Clark SP; Chou ST; Martin TJ; Danks JA
J Pathol; 1995 Jun; 176(2):161-5. PubMed ID: 7636626
[TBL] [Abstract][Full Text] [Related]
2. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
3. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
4. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone-related protein: immunohistochemical localization in cancers and in normal skin.
Danks JA; Ebeling PR; Hayman J; Chou ST; Moseley JM; Dunlop J; Kemp BE; Martin TJ
J Bone Miner Res; 1989 Apr; 4(2):273-8. PubMed ID: 2728930
[TBL] [Abstract][Full Text] [Related]
6. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
7. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
8. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
10. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
11. Pathology of malignant mesothelioma.
Van Marck E
Lung Cancer; 2004 Aug; 45 Suppl 1():S35-6. PubMed ID: 15261431
[TBL] [Abstract][Full Text] [Related]
12. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.
Brockstedt U; Gulyas M; Dobra K; Dejmek A; Hjerpe A
Am J Clin Pathol; 2000 Aug; 114(2):203-9. PubMed ID: 10941335
[TBL] [Abstract][Full Text] [Related]
13. In search of a positive immunohistochemical marker for mesothelioma: an update.
Ordóñez NG
Adv Anat Pathol; 1998 Jan; 5(1):53-60. PubMed ID: 9868512
[No Abstract] [Full Text] [Related]
14. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
15. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone-related protein expression in human gastric adenocarcinomas not associated with hypercalcemia.
Abdeen O; Pandol SJ; Burton DW; Deftos LJ
Am J Gastroenterol; 1995 Oct; 90(10):1864-7. PubMed ID: 7572910
[TBL] [Abstract][Full Text] [Related]
17. Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure.
Tsuzuki T; Ninomiya H; Natori Y; Ishikawa Y
Pathol Int; 2008 Jul; 58(7):451-5. PubMed ID: 18577116
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
Frey AB; Wali A; Pass H; Lonardo F
Histopathology; 2007 May; 50(6):720-6. PubMed ID: 17493236
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone-related protein in patients with primary breast cancer and eucalcemia.
Bucht E; Rong H; Pernow Y; Nordqvist AC; Eriksson E; Rankin W; von Schoultz E; Burtis WJ; Granberg B; Falkmer UG; Burton DW; Deftos LJ
Cancer Res; 1998 Sep; 58(18):4113-6. PubMed ID: 9751621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]